SIRT1 and cancer: SIRT-1 inhibitors have been investigated in prostate cancer as well: EX-527 increased the sensitivity of cancer cells to vesicular stomatitis virus oncolysis [56], while compound 17 [57] (discovered by VS, see Section 3.1) exhibited anti-proliferative effects in vitro.